The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype

Xiaowu Zhang, Ray Wong, Sheryl X. Hao, Warren S. Pear, and Ruibao Ren

Bcr-Abl plays a critical role in the pathogenesis of chronic myelogenous leukemia (CML). It was previously shown that expression of Bcr-Abl in bone marrow cells by retroviral transduction efficiently induces a myeloproliferative disorder (MPD) in mice resembling human CML. This in vivo experimental system allows the direct determination of the effect of specific domains of Bcr-Abl, or specific signaling pathways, on the complex in vivo pathogenesis of CML. In this report, the function of the SH2 domain of Bcr-Abl in the pathogenesis of CML is examined using this murine model. It was found that the Bcr-Abl SH2 mutants retain the ability to induce a fatal MPD but with an extended latency compared with wild type (wt) Bcr-Abl. Interestingly, in contrast to wt Bcr-Abl–induced disease, which is rapid and monophasic, the disease caused by the Bcr-Abl SH2 mutants is biphasic, consisting of an initial B-lymphocyte expansion followed by a fatal myeloid proliferation. The B-lymphoid expansion was diminished in mixing experiments with bcr-ablΔSH2 and wt bcr-abl cells, suggesting that the Bcr-Abl–induced MPD suppresses B-lymphoid expansion. (Blood. 2001;97:277-287)

© 2001 by The American Society of Hematology

Introduction

The bcr-abl oncogene is produced when the break-point cluster region gene (c-bcr) sequences on chromosome 22 are fused to c-abl sequences on chromosome 9 by a reciprocal translocation.1 The Bcr-Abl fusion protein is present in nearly all patients with chronic myelogenous leukemia (CML) and in some patients with acute lymphoblastic leukemia. Depending on the nature of the translocation and exactly how the bcr and abl sequences become spliced into a final bcr-abl messenger RNA, various Bcr-Abl fusion proteins including p185, p210, and p230 can be generated, which show a preferential association with different types of leukemia.2

CML is a clonal myeloproliferative disorder (MPD) resulting from the neoplastic transformation of hematopoietic stem cells.1,3 The disease usually has a biphasic course, comprising a chronic phase and a blast phase. The initial chronic phase is characterized by accumulation of large numbers of myeloid-lineage cells predominated by granulocytes in peripheral blood (PB), bone marrow (BM), and spleen. It is not clear why CML manifests as an MPD, even though Bcr-Abl is expressed in the hematopoietic stem cell compartment in humans and Bcr-Abl has the capacity to transform nearly all hematopoietic elements. Progression of the disease after 3 to 5 years to terminal blast phase, often through an accelerated phase, is characterized by accelerated accumulation of immature myeloid or lymphoid cells. Bcr-Abl is important in both initiation and maintenance of neoplastic transformation; however, disease progression to blast crisis likely requires additional mutations.1,5

Bcr-Abl contains many domains/motifs that regulate and mediate its function. Abl-derived sequences from Bcr-Abl contain Src-homology-3 (SH3), SH2, and tyrosine kinase domains in its N-terminal half, as well as a DNA binding domain, an actin binding domain, nuclear localization signals, and SH3 binding sites in its C-terminal region.6 The Bcr region of Bcr-Abl/p210 contains a coiled-coil oligomerization domain, a serine/threonine kinase domain, a pleckstrin homology domain, a Dbl/CDC24 guanine-nucleotide exchange factor homology domain, and several serine/threonine and tyrosine phosphorylation sites and binding sites for the Abl SH2 domain, Grb2, Grb10, and 14-3-3 proteins.7,8 Defining the roles of these domains/motifs of Bcr-Abl is critical for understanding the molecular mechanism of Bcr-Abl leukemogenesis.

The SH2 domain is a modular unit present in a wide variety of signaling molecules.9,10 It mediates specific protein-protein interactions by binding phosphotyrosine-containing peptides. Some SH2 domains can also bind peptides in a phosphotyrosine-independent manner and some can even bind phospholipids.11-14 The SH2 domains of intracellular protein–tyrosine kinases play a role in the catalytic function of the kinases.15,16 They may contribute to the kinase substrate specificity by protecting the substrates from dephosphorylation, localizing them to a specific subcellular location, or facilitating processive phosphorylation of multiple tyrosine residues in the same protein.17 The SH2 domain plays an important role in the Abl proteins in interacting with and phosphorylating signaling proteins, including p62dok, c-Cbl, Rin-1, Tub, and mDab1.19-24 It can also interact with Bcr sequences and Src through phosphorysine-independent interactions.12,25

The Abl SH2 domain is required for transformation of cultured fibroblast cells by Bcr-Abl.26 However, mutations in the Abl SH2 domain do not diminish the ability of Bcr-Abl to render cytokine-independent growth of factor-dependent hematopoietic cell lines.27-31 In addition, Bcr-Abl SH2 mutants can transform primary lymphoid...
progenitors in vitro as well as wild-type (wt) Bcr-Abl. These conflicting observations in cultured cells suggest that the requirement for the SH2 domain is cell type- or context-dependent. Attempts have also been made to assess the role of the SH2 domain in Bcr-Abl leukemogenesis in vivo. It was shown that the pre-B-lymphoid cells transformed by Bcr-Abl SH2 mutants were poorly tumorigenic in immunodeficient mice. The SH2 domain of Bcr-Abl was also shown to be required for developing a myeloid leukemia in mice due to failure to activate phosphatidylinositol (PI)-3 kinase/Akt pathway. However, in earlier models, Bcr-Abl does not effectively induce CML-like MPD, making it difficult to conclude whether the SH2 domain plays a role in pathogenesis of CML.

We and others recently have shown that expression of Bcr-Abl in BM cells by retroviral transduction efficiently induces an MPD in mice resembling human CML. This murine model for CML provides an effective in vivo experimental system to study the roles and relative importance of domains of Bcr-Abl and of signaling events affected by Bcr-Abl in leukemogenesis.

In this report, we determined which portions of Bcr-Abl/p210 were required for developing an MPD due to failure to activate the PI-3 kinase/Akt pathway. However, in earlier models, Bcr-Abl was also shown to be required for developing a myeloid leukemia in mice due to failure to activate phosphatidylinositol (PI)-3 kinase/Akt pathway. However, in earlier models, Bcr-Abl does not effectively induce CML-like MPD, making it difficult to conclude whether the SH2 domain plays a role in pathogenesis of CML.

We and others recently have shown that expression of Bcr-Abl in BM cells by retroviral transduction efficiently induces an MPD in mice resembling human CML. This murine model for CML provides an effective in vivo experimental system to study the roles and relative importance of domains of Bcr-Abl and of signaling events affected by Bcr-Abl in leukemogenesis. In this report, we used our in vivo model to study the function of Bcr-Abl SH2 domain in the pathogenesis of CML. We found that SH2 mutations slowed the onset of, but did not prevent, Bcr-Abl–induced MPD. The phenotype of the disease induced by Bcr-Abl SH2 mutants differed from that of Bcr-Abl disease in that the SH2 mutants induced a B-lymphoproliferative disorder prior to the fatal MPD. The B–cell lymphocytosis could be suppressed by wt Bcr-Abl–induced MPD in a mixing experiment, suggesting that Bcr-Abl–induced MPD suppresses B-lymphoid expansion. This may provide a clue to the specificity of MPD induction by Bcr-Abl in CML.

**Materials and methods**

**DNA constructs**

The R1057K mutation was introduced into Bcr-Abl/p210 by first amplifying 2 overlapping fragments containing this point mutation from the bcr-abl/p210 gene by polymerase chain reaction (PCR) with 5′ primer NT114: 5′-ATACCGCCTCAACAGTC-3′; and 3′ primer NT112: 5′-CTC TCACCTCTCTCCACCAAGAAGCTGCA TTG-3′. For fragment 1, we used primer NT36 (see above) to amplify the corresponding portion of the bcr-abl/p210 gene to generate bcr-abl/R1057K complementary DNA. To generate bcr-abl/R1057K, we used the 5′ primer NT62: 5′-GAATTCCTGTCACGCTGGAGGCCCATC GTCTATGTTGGTCC-3′ (corresponding to the sequences flanking both ends of the SH2 domain) and 3′ primer NT39 (see above) to amplify the SH2 fragment from bcr-abl/p210 by PCR. The SH2 fragment was digested with HindIII and AvaII and was subcloned into the corresponding position in the bcr-abl/p210 gene to generate bcr-abl/R1057K complementary DNA. To generate bcr-abl/ΔSH2, we used the 5′ primer NT62: 5′-GAATTCCTGTCACGCTGGAGGCCCATC GTCTATGTTGGTCC-3′ (corresponding to the sequences flanking both ends of the SH2 domain) and 3′ primer NT39 (see above) to amplify the SH2 fragment from bcr-abl/p210 by PCR. The SH2 fragment was digested with HindIII and AvaII and was subcloned into the corresponding position in bcr-abl/p210 to generate bcr-abl/ΔSH2 complementary DNA. Both bcr-abl/R1057K and bcr-abl/ΔSH2 were cloned into the EcoRI site in MSCP-IRES-gfp (murine stem cell retroviral vector–internal ribosomal entry site–green fluorescence protein) vector as previously described. 28 The portions of bcr-abl/R1057K and bcr-abl/ΔSH2 that were produced by PCR amplification were verified to be correct by sequencing.

**Cell culture and retrovirus preparation**

NIH3T3 mouse fibroblasts were grown in Dulbecco modified Eagle medium (DMEM) containing 10% calf serum, 100 U/mL penicillin (Gibco BRL, Grand Islands, NY), and 100 μg/mL streptomycin (Gibco BRL). Helper-free retroviruses were generated by transiently transfecting retroviral constructs into BOSC 23 cells as described. 42 Two days after transfection, the culture supernatant containing the retroviruses was collected and used to transduce BM cells for the CML model and NIH3T3 cells for determination of a relative viral titer. The virus preparation can be stored at 4°C for up to 4 days without significant change in virus titer. Retroviral transduction and titering were performed as described. 38,41 All viruses were adjusted to equal titer based on EGF expression with BOSC 23–conditioned medium just before transduction of BM cells or other cell types.

**BM transduction and transplantation**

BM cell transduction and transplantation were performed as previously described. 38

**Flow cytometry and cell sorting**

Flow cytometry and cell sorting were performed as described. 38,41

**Southern blot**

PB obtained from the orbital sinus or tail and dispersed cells from spleen were treated with red blood cell lysis solution ACK (150 mM NaCl, 1 mM KHCO3, 0.1 mM Na2 ethylenediaminetetraacetic acid, pH 7.3). High molecular weight DNA from the white blood cells (WBCs) and sorted splenocytes was isolated by using the QIAamp Blood Kit (Qiagen). For proviral integration analysis, up to 15 μg DNA was digested with either EcoRI, BamHI, or BgII, separated on a 1% agarose gel, transferred to Hybond-N+ membrane (Amersham, Arlington Heights, IL), and hybridized with a probe containing IRES-gfp sequences derived from the retroviral vector as described. 38 For determining the contribution of bcr-abl- and bcr-abl/ΔSH2–transduced cells in BM mixing experiments, genomic DNA from PB was digested with HindIII and separated on a 0.7% agarose gel, transferred to Hybond-N+ membrane, and hybridized with a probe corresponding to a 1.2-kilobase (kb) EcoRI-BglII fragment of the 3′ end of human c-abl complementary DNA. The washed membrane was exposed to X-ray film.

**Immunoblotting**

NIH3T3 cells were transduced with titer-matched viruses as described above. Two days after transfection, cells were serum-starved with DMEM containing 0.1% calf serum for 12 hours. The cells were then collected, washed once in ice-cold phosphate-buffered saline (PBS) (Gibco BRL), and suspended in certain volume in ice-cold PBS, and boiled for 5 minutes in an equal volume of 2× sodium dodecyl sulfate (SDS) sample buffer as described. 43 The ACK-treated spleen cells were resuspended in ice-cold PBS at 2×106 cells/mL, lysed by adding equal volume of 2× SDS sample buffer, and heated at 100°C for 5 minutes. Cell debris was cleared by centrifugation. Equal amounts of total protein of each lysate were run on HEPES, pH 7.4; 150 mM NaCl; 10% glycerol; 1% Triton X-100; 1 mM EDTA; 1.5 mM MgCl2; 1 mM dithiothreitol (DTT); 10 mM NaF; 1 mM sodium orthovanadate; 1 mM freshly made phenylmethylsulfonyl fluoride; 1× complete protease inhibitor cocktail (Boehringer Mannheim, Indianapolis, IN). Cell lysates were quantified with the Coomassie Protein Assay Reagent (Pierce, Rockford, IL) and adjusted to equal concentration with the above lysis buffer. One-milligram total proteins (in 500 μL) was...
immunoprecipitated with anti-Abl antibody Ab-3 as described.43 Immunoprecipitates were washed 3 times in lysis buffer and twice in kinase buffer (10 mM MgCl₂, 1 mM DTT, 50 mM HEPES) and were then aliquoted equally into 3 Eppendorf tubes: 1 for Western blotting and 2 for kinase assays with substrate glutathione-S-transferase (GST)-10a and GST–Crk-II (Long and Ren, unpublished data, 1996), respectively. The p10a was isolated as a Src-SH3 binding polypeptide and subsequently was shown to be part of a signal integrating protein, Sin.44,45 It contains 92 amino acids including a single tyrosyl residue followed by amino acids Asp-Val-Pro. We found that p10a can be phosphorylated by the Abl protein tyrosine kinase in vitro (Long and Ren, unpublished data, 1996). The kinase assay was performed in total volume of 30 μL containing 1 × kinase buffer, 1 μg substrate, 0.5 mM adenosine triphosphate (ATP), and 1.85 × 10⁴ Bq (5 μCi) γ-[³²P]ATP for 30 minutes at room temperature. Kinase reactions were terminated by adding 30 μL 2 × SDS sample buffer and heating at 100°C for 10 minutes. Equal amounts of supernatant were analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography.

Enzyme-linked immunosorbent assay for IL-3 and GM-CSF

PB from the orbital sinus was collected into an Eppendorf tube, incubated at room temperature for 4 hours, and then incubated at 4°C overnight. The samples were spun at 16,000 rpm in a microcentrifuge at 4°C. The supernatant was transferred into a new tube and frozen at −70°C until use. The serum levels of interleukin (IL)-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) were assayed using mouse IL-3 and GM-CSF enzyme-linked immunosorbent assay (ELISA) kit from R & D Systems (Minneapolis, MN) and Endogen (Woburn, MA), respectively.

Results

Bcr-Abl with mutations in its SH2 domain causes a transient B-lymphoproliferative disorder and a delayed MPD in mice

Two Bcr-Abl SH2 mutants were made to study the role of the SH2 domain in Bcr-Abl–mediated leukemogenesis. Bcr-Abl/R1057K is Bcr-Abl with a single arginine-to-lysine mutation (R1057K) in the conserved FLVRES motif of the SH2 domain. This mutation has been shown to significantly reduce the ability of the SH2 domain to bind tyrosine-phosphorylated proteins but does not affect the overall NMR structure of the SH2 domain.46 Bcr-Abl/ΔSH2 is Bcr-Abl with its SH2 domain deleted. To examine the effect of the SH2 mutations on the expression of Bcr-Abl, NIH3T3 cells were transduced with titer-matched retroviruses containing wt bcr-abl or its SH2 mutants. Western blot analysis of the lysates of these cells showed that wt Bcr-Abl, Bcr-Abl/R1057K, and Bcr-Abl/ΔSH2 expressed at the same level in transduced NIH3T3 cells (Figure 1A).

Bcr-Abl and SH2 mutants were transiently expressed in 293T cells, and the kinase activity of the immunoprecipitated Bcr-Abl proteins were measured by an in vitro kinase assay. As shown in Figure 1B, both Bcr-Abl/R1057K and wt Bcr-Abl were equivalent in their ability to phosphorylate themselves and exogenous substrates Crk-II (Figure 1Bi, compare lanes 1 and 3) and 10a (Figure 1Bii, compare lanes 1 and 3). In contrast, deletion of the SH2 domain showed a slight decrease in the ability to phosphorylate exogenous substrates (Figure 1Bii, lane 4) and a more significant reduction in autophosphorylation of Bcr-Abl/ΔSH2 itself (Figure 1Bii, lane 4). Kinase-deficient Bcr-Abl (Figure 1B, lane 2) was used as a negative control. The low level of phosphorylation seen in this control may be due to the presence of endogenous c-Abl (Figure 1Biii).

To examine the leukemogenicity of the SH2 mutants of Bcr-Abl in vivo, we transduced 5-fluorouracil–treated mouse BM cells in vitro with titer-matched retroviruses containing wt bcr-abl or its SH2 mutants and transplanted these cells into lethally irradiated syngeneic recipient mice as previously described.38 Mice transplanted with BM cells transduced with wt bcr-abl virus (Bcr-Abl mice) died within 3 weeks after BM transplantation (BMT) with characteristics of the CML-like syndrome previously described38 (Figure 2). Bcr-Abl/R1057K mice and Bcr-Abl/ΔSH2 mice also developed a fatal disease but with a significantly longer latency than Bcr-Abl mice (Mantel-Cox [log-rank] test χ² = 23.97, P < .0001 and χ² = 30.28, P < .0001, respectively) (Figure 2). In addition, the disease latency of Bcr-Abl/ΔSH2 mice was significantly longer than that of Bcr-Abl/R1057K mice (χ² = 12.93, P = .0003).

The Bcr-Abl/R1057K and Bcr-Abl/ΔSH2 mice not only survived longer than the wt Bcr-Abl mice but also showed different
hematologic manifestations. Because the pathologic consequences observed in mice receiving either Bcr-Abl/R1057K– or Bcr-Abl/D
SH2–transduced BM cells were similar in all respects except latency, the following analysis will focus on the Bcr-Abl/D
SH2 mice unless otherwise stated. Flow cytometric analysis showed that at day 18 after BMT, most GFP
1 cells in PB, spleen, and BM of wt Bcr-Abl mice were myeloid cells (Mac-1
1). Few B-lymphoid cells (CD19
1) were present (Figure 3A, Bcr-Abl). The low level of B-lymphoid cells in Bcr-Abl mice at day 18 after BMT was unlikely due to failure to reconstitute B-cell lymphopoiesis by day 18 after BMT because GFP
1 B-lymphoid cells were present in vector control mice at this time (Figure 3A, vector). In contrast to wt Bcr-Abl mice, there were a large number of GFP
1 B-lymphoid cells in the PB of Bcr-Abl/D
SH2 mice at day 18 after BMT (Figure 3A). This difference is especially apparent in spleen and BM (compare Bcr-Abl and Bcr-Abl/D
SH2 in Figure 3A). Most GFP
1 cells in the BM of wt Bcr-Abl mice were myeloid cells, whereas almost all GFP
1 cells in the BM of Bcr-Abl/D
SH2 mice were B-lymphoid cells (Figure 3A) (Bcr-Abl and Bcr-Abl/D
SH2 mice had a comparable number of cells in their BM, data not shown).

A detailed immunophenotypic analysis was performed on Bcr-Abl/D
SH2 mice to determine the developmental stages of the B-lymphoid cells. As shown in Figure 3B, there are 78% GFP
1 B lymphocytes (CD19
1) in Bcr-Abl/D
SH2 mouse BMT5.16 at day 27 after BMT. Among the GFP
1 cells, 28% cells are B220 high / sIgM high and 66% are B220 low / sIgM low/ (Figure 3Bii). Similar results were observed in other Bcr-Abl/D
SH2 mice. These results suggest that B-lymphoid cells in Bcr-Abl/D
SH2 mice are...
different developmental stages and that Bcr-Abl/ΔSH2 interferes but does not completely block the development of B lymphocytes.

Analysis of Bcr-Abl/ΔSH2 mice at later time points showed that the B-lymphoproliferative disorder in Bcr-Abl/ΔSH2 mice was gradually replaced by a fatal MPD. As shown in Figure 3C, at day 33 after BMT, almost all GFP$^+$ cells were myeloid cells in PB, spleen, and BM of Bcr-Abl/ΔSH2 mice. Like wt Bcr-Abl, Bcr-Abl/ΔSH2 also induced expansion of a large population of bystander (GFP$^-$) myeloid cells (Figure 3A,C). This result suggests that Bcr-Abl/ΔSH2 retains the ability to stimulate proliferation of normal myeloid cells, as described previously for wt Bcr-Abl mice.38

To further reveal the kinetics of the expansion of myeloid and B-lymphoid cells in wt Bcr-Abl mice and Bcr-Abl/ΔSH2 mice, we quantitated myeloid and B-lymphoid cells in these mice at different time points after BMT. We counted the total WBCs in PB and determined the percentages of B-lymphoid and myeloid cells by flow cytometric analysis. We then calculated the absolute number of B-lymphoid cells and myeloid cells by multiplying the total number of WBCs by the percentages of B-lymphoid and myeloid cells, respectively. As shown in Figure 4A, the total number of WBCs in wt Bcr-Abl mice was already elevated at day 14 after BMT and this number increased very quickly until the mice died shortly after. In Bcr-Abl/ΔSH2 mice, on the other hand, the total number of WBCs was low even at day 16 after BMT; it increased slowly at the early phase of disease (from day 13 to day 27 after BMT); and it then increased rapidly in the later phase. As previously described, almost all cells were myeloid cells in wt Bcr-Abl mice independent of whether they had low WBC counts (day 14 after BMT) or high WBC counts (day 17 after BMT) (Figure 4B). In contrast, Bcr-Abl/ΔSH2 mice had fewer myeloid cells even at day 20 after BMT. The number of myeloid cells in Bcr-Abl/ΔSH2 mice increased slowly at the early phase of disease (from day 20 to day 27 after BMT) and then increased rapidly in the later phase. By the time that Bcr-Abl/ΔSH2 mice developed terminal symptoms of lethargy and cachexia, the absolute number of myeloid cells in these mice was similar to that in the wt Bcr-Abl mice (Figure 4B).

The average number of B-lymphoid cells in Bcr-Abl/ΔSH2 mice increased from approximately 50 $\times$ 10$^9$/L (50 000/$\mu$L) at day 20 after BMT to its peak of about 110 $\times$ 10$^9$/L (110 000/$\mu$L) at day 22 (Figure 4B), whereas very few B-lymphoid cells were present in the wt Bcr-Abl mice. However, as the number of myeloid cells steadily increased in Bcr-Abl/ΔSH2 mice, both the absolute number and relative percentage of B cells decreased. There were only about 30 $\times$ 10$^9$/L (30 000/$\mu$L) B-lymphoid cells in Bcr-Abl/ΔSH2 mice by day 30 after BMT. All of the Bcr-Abl/ΔSH2 mice subsequently developed a fatal MPD that was identical to the MPD induced by wt Bcr-Abl. Of the more than 90 Bcr-Abl/ΔSH2 mice analyzed in 7 independent experiments, only 2 mice differed in their disease characteristics. Similar to other ΔSH2 mice, these 2 mice (in the same experiment) developed transient B-lymphocytosis but died of anemia without MPD, possibly due to failure of BM reconstitution.

In summary, the major differences between the Bcr-Abl/ΔSH2 and Bcr-Abl diseases were the increased survival of the Bcr-Abl/ΔSH2 mice and the biphasic nature of the Bcr-Abl/ΔSH2 disease.

Bcr-Abl–induced MPD suppresses Bcr-Abl/ΔSH2–induced B-lymphoproliferative disorder

Bcr-Abl is capable of inducing MPD and lymphoid leukemia in mice, and the disease phenotype seems to be primarily influenced by the target cells.33,34,38,40,47-51 In our model, similar to human CML, the bcr-abl oncogene is targeted into multipotential hematopoietic progenitor cells that give rise to both myeloid and lymphoid cells in mice. Although bcr-abl$^+$ B-lymphoid cells are present in Bcr-Abl mice, expression of wt Bcr-Abl results in the exclusive expansion of myeloid cells.38-40 It is not clear why B-lymphoid cells fail to expand either in CML patients during chronic phase or in Bcr-Abl mice. In contrast to wt Bcr-Abl, the SH2 mutants of Bcr-Abl cause a delay in development of MPD and induce a transient B-lymphoproliferative disorder prior to the fully developed MPD. This result raising the possibility that B-cell proliferation in Bcr-Abl mice may be suppressed by the Bcr-Abl–induced expansion of myeloid cells. This leads to the prediction that Bcr-Abl SH2-mutant–induced B lymphoproliferation would be suppressed by Bcr-Abl–induced myeloid tumors.

To test this possibility, we transduced BM cells with titer-matched bcr-abl virus and bcr-abl/ΔSH2 virus separately and then mixed these transduced BM cells and/or mock-transduced marrow cells at different ratios (Figure 5A) and transplanted a total of 500 000 cells into each lethally irradiated recipient mouse. As we have shown previously, up to one-tenth dilution of bcr-abl–transduced BM cells in mock-transduced BM does not change disease...
phenotypes except for delaying disease onset. Adding 100,000 mock-transduced BM cells to Bcr-Abl/ΔSH2 BM cells did not change the disease phenotypes of Bcr-Abl/ΔSH2 mice (data not shown).

At day 22 after BMT, Bcr-Abl/ΔSH2 mice had an average of 100 × 10⁹/L (100,000/µL) B-lymphoid cells in PB (or 47.7% of WBCs were B cells) (Figure 5B, column 6). However, in a 1:8 (Bcr-Abl/Bcr-Abl/ΔSH2) mix, recipient mice had only 24.6 × 10⁹/L (24,600/µL) B-lymphoid cells on average (column 5) (except for the mouse [BMT11.37] indicated by an arrow, in which only bcr-abl/ΔSH2 cells are expanded, see below), and 1:4 mix BMT mice had only 8.9 × 10⁹/L (8,900/µL) B-lymphoid cells (column 4), even though all of these mice were transplanted with the same number of bcr-abl/ΔSH2–transduced BM cells. The ratio of GFP⁺ B cells to GFP⁻ B cells did not differ significantly among Bcr-Abl/ΔSH2 mice, 1:4 mix mice, and 1:8 mix mice. Furthermore, 1:4 mix BMT mice had much higher total WBC counts (Figure 5B, column 1) than both the 1:8 mix (Figure 5B, column 2) and Bcr-Abl/ΔSH2 alone mice (Figure 5B, column 3), implying that most WBCs of 1:4 mix BM mice at this time (day 22 after BMT) were contributed by wt Bcr-Abl–transduced myeloid cells.

There are 2 possibilities that can account for fewer B-lymphoid cells in the 1:4 mix and 1:8 mix BMT mice. One is that the expansion of myeloid cells suppresses or competes with the expansion of B-lymphoid cells as suggested above. Alternatively, Bcr-Abl–induced disease suppresses establishment of Bcr-Abl/ΔSH2–induced disease.

To distinguish between these possibilities, we investigated the relative amounts of bcr-abl-transduced and bcr-abl/ΔSH2–transduced cells in the mix BMT mice. Because bcr-abl/ΔSH2 is 300 base pairs shorter than bcr-abl, it is possible to quantify the numbers of cells transduced with the 2 constructs through Southern blot analysis. Genomic DNA from PB of various diseased mice was digested with restriction enzyme HindIII to release a 4.6-kb DNA fragment from bcr-abl provirus and a 4.3-kb DNA fragment from bcr-abl/ΔSH2 provirus. The digested genomic DNA was then analyzed by Southern blot with a bcr-abl DNA probe.

As shown in Figure 5C, only the upper band (4.6 kb) is detected in DNA from a Bcr-Abl mouse (Figure 5C, lane 1) and only the lower band (4.3 kb) in DNA from a Bcr-Abl/ΔSH2 mouse (Figure 5C, lane 11). Almost all 1:4 mix BMT mice (Figure 5C, lanes 2-5) and 1:8 mix BMT mice (Figure 5C, lanes 6-10) had upper and lower bands indicative of the upper and lower bands indicated that both bcr-abl and bcr-abl/ΔSH2 cells were expanded at comparable levels in most of the mix BMT mice (Figure 5C, bcr-abl [%] and ΔSH2 [%]). Although bcr-abl/ΔSH2 cells were expanded considerably in all mix BMT mice, all mix BMT mice had very low percentages of B cells (both GFP⁺ and GFP⁻) in their PB compared with Bcr-Abl/ΔSH2 mice (Figure 5C). Furthermore, the absolute number of GFP⁺ B cells was also much lower than expected based on the number of bcr-abl/ΔSH2 cells in the mix BMT mice. For example, at day 20 after BMT, mouse BMT11.39 had a WBC count of 288 × 10⁹/L (288,000/µL), of which 72% were GFP⁺, and 33% of these GFP⁺ cells (determined by Southern blot, Figure 5C) were from bcr-abl/ΔSH2–transduced cells. At the same day, in Bcr-Abl/ΔSH2 mice an average of 30.3% bcr-abl/ΔSH2–transduced (GFP⁺) cells were B-lymphoid cells (GFP⁺CD19⁺). So, BMT11.39 was expected to have 20.73 × 10⁹/L (68.4 × 10⁹/L × 30.3%) GFP⁺ B-lymphoid cells, but instead it had only 0.6%, or 1.73 × 10⁹/L (288 × 10⁹/L × 0.6%) GFP⁺ B-lymphoid cells in PB (Figure 5C)—a nearly 12-fold difference between the expectation and observation. As mentioned previously, there was one 1:8 mix BMT mouse with a very high number of B-lymphoid cells (Figure 5B, column 5, arrow). This particular mouse (BMT11.37) lacked detectable wt bcr-abl–cells (Figure 5C, lane 9). Taken together, the results presented here strongly suggest that Bcr-Abl–induced disease suppresses...
myeloproliferative disease suppresses the Bcr-Abl/ΔSH2–stimulated proliferation of B-lymphoid cells.

The same bcr-abl/ΔSH2–targeted progenitor cells can give rise to both myeloid and B-lymphoid cells

Human CML is a hematopoietic stem cell disease. As described above, Bcr-Abl/ΔSH2 induces both B-lymphoproliferative disorder and MPD in mice. We wondered whether the Bcr-Abl/ΔSH2 myeloid and lymphoid cells originated from the same progenitor cells. To address this question, we purified GFP+CD19+ cells and GFP+Mac-1+ cells from the same Bcr-Abl/ΔSH2 mice by FACSorter. We then checked the proviral integration pattern in these cells by Southern blot analysis after digestion with restriction enzyme EcoRI (Figure 6A). Like wt Bcr-Abl mice,38 multiple clones were expanded in primary Bcr-Abl/ΔSH2 mice (multiple bands with different intensities) (Figure 6A, lanes 3,6). Among the multiple clones from mouse BMT11.53, some were contributed only by B-lymphoid cells (Figure 6A, compare lanes 6 and 8), and some were contributed only by myeloid cells (Figure 6A, compare lanes 6 and 7). However, there was a common band in both B-lymphoid and myeloid cells (Figure 6A, arrowhead). A common band was also found in myeloid cells and B-lymphoid cells in Bcr-Abl/ΔSH2 mouse BMT11.34 (Figure 6A; lanes 1,2; asterisk).

We also found that the Bcr-Abl/ΔSH2–induced disease can be transferred to secondary recipient animals. In one experiment, BM cells isolated from the Bcr-Abl/ΔSH2 BMT primary mouse BMT11.48 at day 28 after BMT (its WBC counts were 126 × 10⁹/L [126 000/L], among which 52.6% were myeloid cells and 44.6% were B cells) were transferred into 5 secondary recipients. Among these 5 recipients, mice BMT11.48.36, BMT11.48.38, and BMT11.48.39 developed diseases. Flow cytometry analysis at day35 after BMT revealed that in secondary recipient mouse BMT11.48.36, 83% of total WBCs were GFP+ myeloid cells, and there were very few (<1%) GFP+ B-lymphoid cells. On the other hand, in mouse BMT11.48.38, 82% of total WBCs were GFP+ B-lymphoid cells and only 1% were GFP+ myeloid cells. Two days later (day 37, blood smears looked the same as on day 35, data not shown), genomic DNA was isolated from PB cells of BMT11.48.36 and BMT11.48.38. The proviral integration patterns in these mice and their parental mouse BMT11.48 were examined by Southern blot analysis (Figure 6A, lanes 3-5). Primary mouse BMT11.48 had more than 6 bands (Figure 6A, lane 3), and secondary mouse BMT11.48.36 had only 1 band (Figure 6A, lane 4), whose source must be myeloid cells. In BMT11.48.38, there was one major band, which must be largely contributed by B-lymphoid cells, and 2 minor bands (Figure 6A, lane 5). The major band in both BMT11.48.36 and BMT11.48.38 was at the same size, suggesting that the myeloid tumor cells in BMT11.48.36 and B-lymphoid tumor cells in BMT11.48.38 originated from the same progenitor...
It was shown that the SH2 domain of Bcr-Abl was required both for activation of Akt and cellular transformation. To test whether the differences in the disease phenotype of Bcr-Abl SH2 mutants versus wt Bcr-Abl are due to their ability to activate Akt, we examined the activation of Akt in diseased mice using an antibody that recognizes the activation-specific phosphorylated site of the protein. Figure 7A shows that Akt is expressed and phosphorylated at a similar level in hematopoietic cells isolated from wt Bcr-Abl, Bcr-Abl SH2 mutant, and vector mice. Similar results were also seen in serum-starved NIH3T3 cells containing wt Bcr-Abl, Bcr-Abl SH2 mutants, or vector alone (Figure 7B). Because Akt is activated in vector control mice and NIH3T3 cells, it is not clear whether Akt can be activated by Bcr-Abl SH2 mutants in these cells, but our results suggest that the changed disease phenotype of Bcr-Abl SH2 mutants may not be due to the ability of the mutants to activate Akt.

Activation of Ras and STAT5 has also been shown to be important for Bcr-Abl transformation. We went on to examine the activation of extracellular signal-regulated kinase (Erk)1/2, a major downstream signaling protein of the Ras pathway, and STAT5 using antibodies that recognize activation-specific phosphorylated sites of these signaling proteins. Figure 7A shows that p42/Erk2 is phosphorylated in cells isolated from both wt Bcr-Abl and Bcr-Abl SH2 mutants.

Figure 7. Expression of Bcr-Abl proteins and activation of Akt, Erk, and STAT5 in vivo and in vitro. Western blot analyses of spleen cell lysates from 2 vector mice (lanes 1,2), 3 wt Bcr-Abl mice (lanes 3-5), 3 Bcr-Abl/R1057K mice (lanes 6-8), and 3 Bcr-Abl/ΔSH2 mice (lanes 9-11) (A) and of lysates of NIH3T3 cells transfected with titer-matched viruses carrying vector alone (lane 1), bcr-abl/R1057K (lane 2), bcr-abl/ΔSH2 (lane 3), or wt bcr-abl (lane 4) (B). The NIH3T3 cells were serum-starved for 12 hours 2 days after transduction. Equal amounts of total lysates of either spleen cells or NIH3T3 cells were separated on 6% to 15% polyacrylamide gradient gels, transferred to nitrocellulose filters, and probed with antibodies as indicated. The fresh filters were first probed with an anti-Abl antibody (Ab-3) or the phospho-specific antibodies against activated Akt, Erk, and STAT5 and then stripped and reprobed with an anti-Dynamin antibody or antibodies against corresponding Akt, Erk, and STAT5 proteins, respectively.

Table 1. Serum level of IL-3 and GM-CSF in mice

<table>
<thead>
<tr>
<th>Mouse group</th>
<th>Mice, no.</th>
<th>IL-3 (pg/mL)*</th>
<th>GM-CSF (pg/mL)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal/vector control</td>
<td>8 (6/2)‡</td>
<td>&lt; 2.5‡</td>
<td>&lt; 5§</td>
</tr>
<tr>
<td>Bcr-Abl/p210</td>
<td>3</td>
<td>7.8 ± 2.4</td>
<td>24.7 ± 9.6</td>
</tr>
<tr>
<td>R1057K/p210</td>
<td>6</td>
<td>5.2 ± 2.7 (0.107)</td>
<td>22.5 ± 9.4 (0.378)</td>
</tr>
<tr>
<td>ΔSH2/p210</td>
<td>12</td>
<td>7.6 ± 5.2 (0.473)</td>
<td>17.5 ± 7.8 (0.096)</td>
</tr>
<tr>
<td>WBC containing &lt; 18% B cells</td>
<td>5</td>
<td>8.8 ± 8</td>
<td>23.4 ± 4.0</td>
</tr>
<tr>
<td>WBC containing ≥ 18% B cells</td>
<td>7</td>
<td>6.8 ± 2.2 (0.302¶)</td>
<td>13.3 ± 7.2 (0.006¶)</td>
</tr>
</tbody>
</table>

*Results shown as average ± SD.
†Six age-matched normal mice and 2 vector control mice.
‡Sensitivity of IL-3 ELISA kit was less than 2.5 pg/mL IL-3.
§Sensitivity of GM-CSF ELISA kit was less than 5 pg/mL GM-CSF.
¶The possibility value of Student t test comparing with wild-type Bcr-Abl mice.
SH2 mutant mice. Both p44/Erk1 and p42/Erk2 were activated in cells isolated from vector control mice (Figure 7B, lanes 1,2). Both p44/Erk1 and p42/Erk2 were also activated in NIH3T3 cells containing wt Bcr-Abl, Bcr-Abl SH2 mutants, or vector alone (Figure 7B). It is not clear why p44/Erk1 was not activated in cells isolated from diseased Bcr-Abl mice.

Activation of STAT5 was detected in total spleen cells from both wt Bcr-Abl and Bcr-Abl SH2 mutant mice but not in spleen cells from the vector control mice (Figure 7A), confirming that Bcr-Abl proteins can induce STAT5 activation directly or indirectly (ie, through induced cytokine signaling) or both. To evaluate the ability of Bcr-Abl SH2 mutants to activate STAT5 directly, we measured the amount of activated phospho-STAT5 in NIH3T3 cells infected with wt Bcr-Abl, Bcr-Abl/R1057K, Bcr-Abl/ΔSH2, and vector alone (Figure 7B). STAT5 was not activated in vector control NIH3T3 cells serum-starved for 12 hours but was activated in Bcr-Abl–expressing NIH3T3 cells under the same condition (Figure 7B). Interestingly, Bcr-Abl/ΔSH2 had a greatly reduced (approximately 3-fold reduction) ability to activate STAT5 compared with wt Bcr-Abl (Figure 7B). However Bcr-Abl/R1057K retained the same STAT5 activation capability as wt Bcr-Abl. Because both Bcr-Abl/R1057K and Bcr-Abl/ΔSH2 caused a similar disease in mice, the changed disease phenotype of Bcr-Abl SH2 mutants may not be due to the ability of the mutants to activate STAT5.

Discussion

Our results show that the SH2 domain of Bcr-Abl is not required to induce a fatal MPD. However, the signaling pathways initiated by the SH2 domain of Bcr-Abl influence the disease latency and phenotype. Most strikingly, in contrast to wt Bcr-Abl–induced disease, which is rapid and monophasic, the disease caused by the Bcr-Abl SH2 mutants is biphasic, consisting of an initial B-lymphocyte expansion followed by a fatal myeloid proliferation. Although the degree of lymphocytosis is severe, it can be suppressed by Bcr-Abl–induced MPD.

The delayed expansion of myeloid cells in Bcr-Abl SH2 mutant mice is unlikely caused by the preceding B-lymphoproliferative disorder for the following 2 reasons: (1) Bcr-Abl SH2 mutants induced the outgrowth of fewer myeloid colonies from 5-fluorouracil–treated BM cells than wt Bcr-Abl in BM colony assays (data not shown); and (2) the B-lymphoproliferative disorder did not delay the MPD induced by wt Bcr-Abl; instead it was suppressed by Bcr-Abl–induced MPD in BM mixing experiments (Figure 5). These observations indicate that Bcr-Abl SH2 mutants have a diminished ability to stimulate myeloid proliferation.

The mechanism underlying the differences in the diseases caused by the SH2 mutants and wt Bcr-Abl is not completely understood. It appears unlikely to be caused by differences in tyrosine kinase activity or differences in retroviral titer. In support of the former, both the SH2 point mutant and deletion mutant cause nearly identical clinical diseases in mice. Despite the in vitro kinase activity being lower in the deletion mutant, the activity in the point mutant is similar to wt Bcr-Abl (Figure 1). The lower kinase activity in the deletion mutant may only account for a further delay of disease onset in Bcr-Abl/ΔSH2 mice compared with Bcr-Abl/R1057K mice (Figure 2). In support of the latter, we have previously shown that even though 10-fold dilution in retroviral supernatant slowed the onset of MPD from 3 weeks to 5 weeks, these mice did not develop the B-lymphocytosis observed in the Bcr-Abl SH2 mutant mice.38 These results support the notion that specific SH2-generated signals, rather than the overall Abl kinase activity, account for the differences in disease phenotypes.

It has been reported that the Abl SH2 domain was required for Bcr-Abl–induced IL-3 production in the FDCP-1 myeloid cell line.34 However, we detected similar levels of IL-3 and GM-CSF in serum of both Bcr-Abl and Bcr-Abl SH2 mutant mice (Table 1). We also found that Bcr-Abl SH2 mutants induced expansion of a large population of bystander (GFP)– myeloid cells (Figure 3A,C), suggesting that Bcr-Abl/ΔSH2 retains the ability to stimulate proliferation of normal myeloid cells, as described previously for wt Bcr-Abl mice.38 The difference in the ability of Bcr-Abl SH2 mutants to induce cytokine production in vivo versus in the FDCP-1 myeloid cell line may be due to a different cellular context or to different environment—eg, growth factor signaling in an in vivo environment may complement some of the defects of the SH2 mutation. Nevertheless, our results indicate that the changed disease latency and phenotype in Bcr-Abl SH2 mutant mice is not due to an altered production of IL-3 and GM-CSF, although we could not exclude the possibilities that Bcr-Abl may induce production of other cytokines and that the SH2 domain of Bcr-Abl may be important for production of those cytokines.

The SH2 domain of Bcr-Abl has been shown to play an important role in interacting with and regulating phosphorylation of signaling proteins, including p62dok, c-Cbl, Rin-1, and Shc.18-22,25 The SH2 mutations abrogate the ability of Bcr-Abl to either interact or phosphorylate these proteins, which may affect multiple downstream signaling pathways. Of particular interest, the SH2 domain of Bcr-Abl has been shown to be required both for activation of the PI-3 kinase/Akt pathway and cellular transformation.25 However, we found that Akt was activated in Bcr-Abl SH2 mutant cells in mice (Figure 7A). Although we do not know whether Akt was activated by Bcr-Abl SH2 mutants or by growth factor signaling within mice or by both, the ability of Bcr-Abl SH2 mutants to activate Akt appears not to account for the changed disease latency and phenotype in Bcr-Abl SH2 mutant mice. Similarly, there was no significant difference in Erk activation in cells isolated from both wt Bcr-Abl and Bcr-Abl SH2 mutant mice (Figure 7A). In contrast to the aforementioned signaling pathways, Bcr-Abl/ΔSH2 showed a significantly reduced ability to activate STAT5 in NIH3T3 cells (Figure 7B). However, the ability of Bcr-Abl/R1057K to activate STAT5 is similar to wt Bcr-Abl (Figure 7). Because the pathologic consequences observed in mice receiving either Bcr-Abl/R1057K– or Bcr-Abl/ΔSH2–transduced BM cells were similar in all respects except latency, reduced activation of STAT5 may not account for the phenotypic changes of the Bcr-Abl SH2 mutants. The reduced ability of Bcr-Abl/ΔSH2 in activating STAT5 may be due to its reduced kinase activity and may account for the further delay of disease onset compared with Bcr-Abl/R1057K. Consistent with the latter notion, STAT5 has been shown to regulate proliferation, differentiation, and apoptosis in hematopoietic cells39 and to play a critical role in myelopoiesis and erythropoiesis in non–steady-state conditions, such as during the rapid expansion of cells under stress/pathologic conditions or during embryonic development.60,61 In addition, it was found that dominant-negative STAT5 inhibits the growth of the K562 and 32Dce13 cells.62-64

CML is a clonal multilineage MPD. Although hypercellularity occurs in multiple lineages such as Ph+ erythroid and B-lymphoid cells, granulocytosis is predominant in CML patients. A similar phenomenon is observed in the murine model for CML.38-40 It is not clear why the disease is manifested as an MPD, even though
Bcr-Abl is expressed in the hematopoietic stem cell compartment in humans and Bcr-Abl has the capacity to transform nearly all hematopoietic elements. Our findings that SH2 mutants of Bcr-Abl induced a transient B-lymphoproliferative disorder prior to a delayed MPD and that the lymphocytosis can be suppressed by Bcr-Abl–induced MPD (Figures 4 & 5) indicate that the Bcr-Abl–induced MPD suppresses lymphoid expansion. Suppression of the B-lymphoid expansion by the rapidly occurring MPD may be one of the mechanisms that account for the lack of B-lymphoproliferative disorder observed in CML patients and in Bcr-Abl mice. One possible mechanism underlying the suppression of B lymphoproliferation by Bcr-Abl–induced MPD is that myeloid cells may compete with lymphoid cells for hematopoietic space or cytokines required for proliferation of both cell types. Alternatively, Bcr-Abl may directly or indirectly induce production of inhibitors for lymphoproliferation. A similar mechanism may prevent erythroid expansion, because Bcr-Abl is capable of functionally replacing the erythropoietin receptor (EpoR) and supporting proliferation, differentiation, and maturation of fetal liver erythroid progenitors from EpoR–/– mice.56 Yet, CML patients do not manifest erythrocytosis.

In several in vivo models, Bcr-Abl induces a pre-B (IgM–) lymphoblastic leukemia.33,34,40,47,48,50,51 In Bcr-Abl SH2 mutant mice, however, we found that many GFP+ B-lymphoid cells were surface IgM+ (sIgM+)(Figure 3Bii), suggesting that Bcr-Abl SH2 mutants are not efficient for leukemic transformation in the presence of a concomitant MPD. It is possible that the SH2-linked signaling pathways are important for Bcr-Abl to block the development of B lymphocytes.

The TEL/PDGFβR fusion protein, generated by t(5;12)(q33;p13) translocation in a subset of chronic myelomonocytic leukemia, was also shown to induce a fatal MPD in mice.65 An in vivo mutation analysis using the murine BM transduction/transplantation model showed that specific mutations that affect specific signaling pathways have different effects on disease phenotype.66 Similar to Bcr-Abl SH2 mutants, mutation of the tyrosine residues essential for the binding of PI3K, Nck, Ras-GAP, SHP-2, and PLCγ in TEL/PDGFβR did not affect the phenotype of the MPD but extended the disease latency.66 However, no documented B-lymphoproliferative disorder occurred prior to the myeloid disease. These data are also consistent with our data showing that the B-lymphoproliferative disorder induced by Bcr-Abl SH2 mutants is not simply a result of delayed MPD. It will be of interest to identify both common signaling pathways important for myeloproliferation induced by Bcr-Abl and TEL/PDGFβR and specific signaling events that lead to B lymphoproliferation in Bcr-Abl SH2 mutant mice.

Acknowledgments
We thank Ben Hentel and Jonathan Schatz for their help on flow cytometry.

References
34. Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukemia in man,


The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype

Xiaowu Zhang, Ray Wong, Sheryl X. Hao, Warren S. Pear and Ruibao Ren